Signaturefd, LLC Seagen Inc. Transaction History

Signaturefd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 03, 2023	BUY	$191.51 - $216.16 $25,087 - $28,316	131 Added 6.47%	2,157 $457,000
Q2 2023 Aug 01, 2023	SELL	$187.64 - $206.25 $7,693 - $8,456	-41 Reduced 1.98%	2,026 $389,000
Q1 2023 Apr 28, 2023	BUY	$127.59 - $203.08 $107,813 - $171,602	845 Added 69.15%	2,067 $418,000
Q4 2022 Jan 27, 2023	SELL	$117.37 - $139.17 $26,760 - $31,730	-228 Reduced 15.72%	1,222 $157,000
Q3 2022 Nov 08, 2022	SELL	$135.27 - $180.11 $7,304 - $9,725	-54 Reduced 3.59%	1,450 $198,000
Q2 2022 Aug 10, 2022	BUY	$108.81 - $179.33 $36,016 - $59,358	331 Added 28.22%	1,504 $266,000
Q1 2022 May 02, 2022	BUY	$119.61 - $157.85 $73,799 - $97,393	617 Added 110.97%	1,173 $169,000
Q4 2021 Jan 25, 2022	SELL	$142.57 - $190.86 $22,953 - $30,728	-161 Reduced 22.45%	556 $86,000
Q3 2021 Oct 28, 2021	BUY	$142.45 - $169.82 $33,190 - $39,568	233 Added 48.14%	717 $122,000
Q2 2021 Jul 26, 2021	BUY	$135.08 - $161.1 $10,806 - $12,888	80 Added 19.8%	484 $76,000
Q1 2021 Apr 30, 2021	BUY	$137.51 - $190.8 $7,838 - $10,875	57 Added 16.43%	404 $56,000
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $57,126 - $73,539	347 New	347 $61,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.